Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis.

Dimango E, Walker P, Keating C, Berdella M, Robinson N, Langfelder-Schwind E, Levy D, Liu X.

BMC Pulm Med. 2014 Feb 15;14:21. doi: 10.1186/1471-2466-14-21.

PMID:
24528942
[PubMed - in process]
Free PMC Article
2.

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.

PMID:
23818295
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

PMID:
23810128
[PubMed - indexed for MEDLINE]
4.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

PMID:
21705017
[PubMed - indexed for MEDLINE]
5.

Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis.

Sontag MK, Quittner AL, Modi AC, Koenig JM, Giles D, Oermann CM, Konstan MW, Castile R, Accurso FJ; Investigators and Coordinators of the Airway Secretion Clearance Trial.

Pediatr Pulmonol. 2010 Mar;45(3):291-300. doi: 10.1002/ppul.21179.

PMID:
20146387
[PubMed - indexed for MEDLINE]
6.

Genetic modifiers of liver disease in cystic fibrosis.

Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkov√° D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group.

JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.

PMID:
19738092
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF.

J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16.

PMID:
19608199
[PubMed - indexed for MEDLINE]
8.

Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population.

Giusti R; New York State Cystic Fibrosis Newborn Screening Consortium.

Pediatr Pulmonol. 2008 Jul;43(7):638-41. doi: 10.1002/ppul.20824.

PMID:
18500736
[PubMed - indexed for MEDLINE]
9.

Metabolic alkalosis and cystic fibrosis.

Baird JS, Walker P, Urban A, Berdella M.

Chest. 2002 Aug;122(2):755-6. No abstract available.

PMID:
12171867
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk